HS Code:
Dihydrostreptomycin and its derivatives; salts thereof fall under the Harmonized System (HS) Code 294120, which pertains to antibiotics. Dihydrostreptomycin is an aminoglycoside antibiotic derived from streptomycin, primarily used in veterinary medicine to treat bacterial infections in animals. Its derivatives and salts are chemical variations that enhance its efficacy or stability. This category is a niche segment within the broader pharmaceutical and antibiotic trade, often subject to strict regulatory oversight due to concerns over antibiotic resistance and usage in agriculture.
Total Trade Volume
Approximately $50 million USD
Data from 2022
Source
United Nations Comtrade Database and World Trade Organization (WTO) statistics
$20 million USD
40% of total trade of total trade
Increasing
$10 million USD
20% of total trade of total trade
Increasing
$8 million USD
16% of total trade of total trade
Stable
$5 million USD
10% of total trade of total trade
Stable
$3 million USD
6% of total trade of total trade
Decreasing
Average Rate
5.2% ad valorem
Highest Rate
12% (imposed by certain developing countries to protect local industries)
Lowest Rate
0% (under free trade agreements such as EU-USMCA or within the EU)
Rising demand in veterinary applications
Increased trade volume in developing countries with large livestock sectors, such as India and Brazil, due to growing meat production
2021-2022
Regulatory tightening in developed markets
Reduced usage in the EU and US due to policies aimed at combating antibiotic resistance, shifting trade to alternative antibiotics or non-antibiotic solutions
2020-2022
Shift towards sustainable alternatives
Emerging research into probiotics and other non-antibiotic treatments is beginning to impact the market share of dihydrostreptomycin derivatives
2022
The European Union implemented stricter regulations on the use of antibiotics in livestock, including dihydrostreptomycin, to curb antimicrobial resistance.
January 2022
Reduced exports to EU countries, prompting exporters like China to focus on markets in Asia and Africa.
China announced investments in antibiotic production facilities to meet growing global demand for veterinary antibiotics, including dihydrostreptomycin derivatives.
March 2023
Likely to reinforce Chinaโs dominance in the market, potentially lowering global prices due to economies of scale.
The World Health Organization released updated guidelines urging reduced use of critical antibiotics like dihydrostreptomycin in agriculture.
November 2022
Increased scrutiny and potential trade barriers in countries adopting WHO recommendations, affecting market dynamics.